$-1.48 EPS Expected for Alnylam Pharmaceuticals, Inc. (ALNY)

April 21, 2018 - By Ellis Scott

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) LogoInvestors sentiment increased to 2.03 in 2017 Q4. Its up 1.11, from 0.92 in 2017Q3. It improved, as 27 investors sold Alnylam Pharmaceuticals, Inc. shares while 47 reduced holdings. 67 funds opened positions while 83 raised stakes. 90.18 million shares or 4.83% more from 86.02 million shares in 2017Q3 were reported.
Kbc Grp Inc Nv invested in 0.01% or 7,666 shares. Hsbc Public Limited Co stated it has 0% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). 16,157 were accumulated by Comerica Bancshares. Public Employees Retirement Association Of Colorado, a Colorado-based fund reported 17,321 shares. Jane Street Grp Inc Limited Liability Corp holds 0% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 3,250 shares. Fmr Ltd Liability Corp reported 0.22% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Glg Ptnrs Limited Partnership reported 1,200 shares. Glenmede Tru Com Na accumulated 0% or 175 shares. Us National Bank & Trust De invested in 241 shares or 0% of the stock. Gilder Gagnon Howe Communication Ltd Liability Corporation holds 2.08% or 1.22 million shares in its portfolio. Alkeon Capital Management Limited Liability Company, New York-based fund reported 5,000 shares. Natixis Asset reported 0.07% stake. Evercore Wealth Mngmt Ltd Llc holds 600 shares or 0% of its portfolio. Knott David M holds 0.01% or 249 shares. Apg Asset Nv reported 0% stake.

Since January 4, 2018, it had 0 buys, and 10 sales for $38.04 million activity. Vaishnaw Akshay had sold 88,554 shares worth $12.67 million on Wednesday, March 14. $2.57 million worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was sold by Ausiello Dennis A. 7,221 shares were sold by Greenstreet Yvonne, worth $985,958 on Monday, March 26. The insider SCHIMMEL PAUL sold $4.17 million. 38,460 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares with value of $5.50 million were sold by Greene Barry E. SHARP PHILIP A sold $1.94M worth of stock or 15,000 shares.

Analysts expect Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report $-1.48 EPS on May, 4.They anticipate $0.23 EPS change or 18.40 % from last quarter’s $-1.25 EPS. After having $-1.48 EPS previously, Alnylam Pharmaceuticals, Inc.’s analysts see 0.00 % EPS growth. The stock increased 1.34% or $1.29 during the last trading session, reaching $97.48. About 875,228 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 150.73% since April 21, 2017 and is uptrending. It has outperformed by 139.18% the S&P500.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Coverage

Among 15 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 11 have Buy rating, 1 Sell and 3 Hold. Therefore 73% are positive. Alnylam Pharmaceuticals had 30 analyst reports since October 30, 2017 according to SRatingsIntel. Credit Suisse maintained it with “Outperform” rating and $154 target in Tuesday, March 13 report. The rating was maintained by Jefferies on Monday, January 8 with “Buy”. The firm has “Buy” rating by J.P. Morgan given on Thursday, November 9. The stock has “Buy” rating by JMP Securities on Tuesday, April 3. Piper Jaffray maintained it with “Buy” rating and $188.0 target in Thursday, November 2 report. FBR Capital maintained the shares of ALNY in report on Monday, December 11 with “Buy” rating. As per Friday, February 9, the company rating was maintained by Morgan Stanley. FBR Capital maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Monday, January 8 with “Buy” rating. Piper Jaffray maintained it with “Buy” rating and $182.0 target in Friday, December 15 report. The firm has “Buy” rating by Needham given on Friday, November 3.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The company has market cap of $9.77 billion. The Company’s pipeline of investigational RNAi therapeutics is focused on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. It currently has negative earnings. The company??s clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of transthyretin-mediated amyloidosis ; Fitusiran, an investigational RNAi therapeutic that is in Phase I/II clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran (ALN-PCSsc), which is in Phase II clinical trial for hypercholesterolemia.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: